Highlights of EASD presentations by Sanofi and Novo Nordisk

13 September 2016

The 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) is now taking place in Munich, Germany, and included some notable new data presentations.

Among these, French pharma major Sanofi (Euronext: SAN) announced today that adults with type 2 diabetes treated with Toujeo (insulin glargine 300 Units/mL) experienced a consistently lower rate of confirmed or severe hypoglycemia both at night and at any time of the day compared with those treated with Lantus (insulin glargine 100 Units/mL), at all levels of HbA1c (average blood glucose over the previous three months) achieved at month 6.

Sanofi is conducting three large, randomized clinical trials - ACHIEVE, REACH and REGAIN CONTROL - evaluating in real-life conditions the effect of Toujeo in people with type 2 diabetes. These trials will provide an important evaluation of the effectiveness of Toujeo's disease-management strategy that could be particularly relevant to healthcare professionals, diabetes educators and payers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK